| dc.creator |
COVİC, Adrian |
|
| dc.creator |
ORTİZ, Alberto |
|
| dc.creator |
Kanbay, Mehmet |
|
| dc.creator |
Afsar, Rengin Elsurer |
|
| dc.creator |
AFŞAR, Barış |
|
| dc.date |
2018-06-30T21:00:00Z |
|
| dc.date.accessioned |
2020-10-06T11:24:45Z |
|
| dc.date.available |
2020-10-06T11:24:45Z |
|
| dc.identifier |
d398a3ca-e833-481b-b7ea-0764d01ad380 |
|
| dc.identifier |
10.1007/s40265-018-0942-2 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/d398a3ca-e833-481b-b7ea-0764d01ad380/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/72916 |
|
| dc.description |
Interleukin (IL)-1 alpha and IL-1 beta are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1 beta antibodies (canakinumab) and IL-1 beta traps (rilonacept) are in clinical use to treat these diseases. Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
The Future of IL-1 Targeting in Kidney Disease |
|
| dc.type |
info:eu-repo/semantics/article |
|